Article information
Full text is only aviable in PDF
References
[1]
Murray CJ, López AD.
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study.
Lancet, 349 (1997), pp. 1498-1504
[2]
López AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al.
Chronic obstructive pulmonary disease: current burden and future projections.
Eur Respir J., 27 (2006), pp. 397-412
[3]
Instituto Nacional de Estadística [cited 2005 Nov 2].
[5]
Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al.
The Global Burden of COPD: epidemiology and costs of COPD.
Eur Respir J., 27 (2006), pp. 188-207
[6]
Sobradillo V, Miravitlles M, Jiménez MA, Gabriel R, Viejo JL, Fernando J, et al.
Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo.
Arch Bronconeumol, 35 (1999), pp. 159-166
[7]
Izquierdo JL.
The burden of COPD in Spain: results from the Confronting COPD Survey.
Respir Med., 97 (2003), pp. S61-SS7
[8]
Banegas JR, Díez Gañán L, González Enríquez J, Villar Álvarez F, et al.
La mortalidad atribuible al tabaquismo comienza a descender en España.
Med Clin (Barc), 124 (2005), pp. 769-771
[9]
Masa JF, Sobradillo V, Villasante C, Jiménez-Ruiz CA, Fernández-Fau L, Viejo JL, et al.
Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional.
Arch Bronconeumol, 40 (2004), pp. 72-79
[10]
Izquierdo JL, De Miguel J.
Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease.
J COPD, 1 (2004), pp. 215-223
[11]
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med., 142 (2005), pp. 233-239
[12]
Celli BR, MacNee W.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J., 23 (2004), pp. 932-946
[13]
Barberá JA, Peces-Barba G, Agustí AG, Izquierdo JL, Monsó E, Montemayor T, et al.
Guía práctica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[14]
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary.
Am J Respir Crit Care Med., 163 (2001), pp. 1256-1276
[15]
Vestbo J, The TORCH Study Group.
The TORCH (TOwards a Revolution in COPD Health) survival study protocol.
Eur Respir J., 24 (2004), pp. 206-210
[16]
Sin DD, Wu L, Anderson J, Anthonisen N, Buist AS, Burge PS, et al.
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.
Thorax, 60 (2005), pp. 992-997
[17]
Samet JM.
Inhaled corticosteroids and chronic obstructive pulmonary disease: new and improved evidence?.
Am J Respir Crit Care Med., 172 (2005), pp. 407-408
[18]
Sin DD, Anthonisen NR, Soriano JB, Agusti AGN.
Role of comorbidities in COPD mortality.
Eur Respir J., (2006),
[19]
Hansell AL, Walk JA, Soriano JB.
What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis.
Eur Respir J., 22 (2003), pp. 809-814
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
